Zobrazeno 1 - 10
of 170
pro vyhledávání: '"Brian B. Hasinoff"'
Publikováno v:
Molecules, Vol 23, Iss 8, p 2041 (2018)
As part of our initial efforts into developing a tumor-targeting therapy, C-10 substituted derivatives of a camptothecin analog (SN-38) have been synthesized (2-, 3- and 4-nitrobenzyl) for use as potential hypoxia-activated prodrugs and evaluated for
Externí odkaz:
https://doaj.org/article/89d8f134264c4297903730b8fc37fdc7
Autor:
Daywin Patel, Brian B. Hasinoff
Publikováno v:
Cardiovascular Toxicology. 20:380-389
The anticancer drug dasatinib (Sprycel) is a BCR-ABL1-targeted tyrosine kinase inhibitor used in treating chronic myelogenous leukemia that has been shown in clinical trials to display cardiovascular toxicities. While dasatinib potently inhibits BCR-
Publikováno v:
Cardiovascular Toxicology. 20:312-320
Dexrazoxane is clinically used to reduce doxorubicin cardiotoxicity and anthracycline-induced extravasation injury. Dexrazoxane is a strong catalytic inhibitor of topoisomerase II. It can also undergo metabolism to form an iron-binding analog of EDTA
Publikováno v:
Toxicology and applied pharmacology. 399
The cardiotoxicity caused by doxorubicin and extravasation injury caused by anthracyclines is reduced by the clinically approved bisdioxopiperazine drug dexrazoxane. Dexrazoxane is a rings-closed analog of EDTA and is hydrolyzed in vivo to a form tha
Autor:
Brian B. Hasinoff
Publikováno v:
Archives of Biochemistry and Biophysics. 639:52-58
Bortezomib, carfilzomib, ixazomib, oprozomib, and delanzomib are anticancer drugs that target the proteasomal system. Carfilzomib and oprozomib are epoxyketones that form an irreversible covalent bond with the 20S proteasome, whereas bortezomib, ixaz
Autor:
Daywin Patel, Brian B. Hasinoff
Publikováno v:
Archives of Biochemistry and Biophysics. 633:23-28
The alcohol abuse drug disulfiram has also been shown to exhibit potent cell growth inhibitory and anticancer activity. While a number of cellular and animal studies have suggested that disulfiram exhibits its anticancer activity through interaction
Autor:
Daywin Patel, Soumendrakrishna Karmahapatra, Brian B. Hasinoff, Ragu Kanagasabai, Xing Wu, Jack C. Yalowich
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 356:397-409
Pixantrone is a new noncardiotoxic aza-anthracenedione anticancer drug structurally related to anthracyclines and anthracenediones, such as doxorubicin and mitoxantrone. Pixantrone is approved in the European Union for the treatment of relapsed or re
Publikováno v:
Molecules, Vol 23, Iss 8, p 2041 (2018)
Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry
Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry
As part of our initial efforts into developing a tumor-targeting therapy, C-10 substituted derivatives of a camptothecin analog (SN-38) have been synthesized (2-, 3- and 4-nitrobenzyl) for use as potential hypoxia-activated prodrugs and evaluated for
Autor:
Brian B. Hasinoff, Daywin Patel
Publikováno v:
Cardiovascular toxicology. 18(6)
The proteasome inhibitors bortezomib, carfilzomib, and ixazomib, which are used in the treatment of multiple myeloma have greatly improved response rates. Several other proteasome inhibitors, including delanzomib and oprozomib, are in clinical trials
Publikováno v:
Progress in Pediatric Cardiology. 36:33-38
We review here the experiments by which dexrazoxane was identified as a protectant against two serious anthracycline toxicities: cardiotoxicity and accidental extravasation injury. These experiments led to the successful use of dexrazoxane as a cardi